Patent classifications
A61K31/164
Ceramide-Rubusoside Nanomicelles and Their Use in Cancer Therapy
Water-soluble, cell-permeable nanomicelles containing ceramides and a steviol glycoside, such as rubusoside, are disclosed. The ceramide-steviol glycoside complex has high water solubility, and can be used for treating cancers with p53 mutations. Preliminary results have shown that the Cer nanomicelles are effective in restoring p53 protein expression, and that they are functionally dominant over p53 mutants. The novel nanomicelles restore a wild-type phenotype, and have very low toxicity to noncancerous cells. The novel Cer nanomicelles may be used in treating p53-associated cancers.
Ceramide-Rubusoside Nanomicelles and Their Use in Cancer Therapy
Water-soluble, cell-permeable nanomicelles containing ceramides and a steviol glycoside, such as rubusoside, are disclosed. The ceramide-steviol glycoside complex has high water solubility, and can be used for treating cancers with p53 mutations. Preliminary results have shown that the Cer nanomicelles are effective in restoring p53 protein expression, and that they are functionally dominant over p53 mutants. The novel nanomicelles restore a wild-type phenotype, and have very low toxicity to noncancerous cells. The novel Cer nanomicelles may be used in treating p53-associated cancers.
Combination of cannabinoids and n-acylethanolamines
The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.
Combination of cannabinoids and n-acylethanolamines
The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.
Combination of cannabinoids and n-acylethanolamines
The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.
IMMUNOSUPPRESSIVE BLOOD CELLS AND METHODS OF PRODUCING THE SAME
The present invention refers to a method of producing immunosuppressive bleed cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease.
IMMUNOSUPPRESSIVE BLOOD CELLS AND METHODS OF PRODUCING THE SAME
The present invention refers to a method of producing immunosuppressive bleed cells that can be used for the treatment of autoimmune diseases, in particular multiple sclerosis, organ graft rejection and graft-versus-host disease.
HAIR GROWTH-PROMOTING COMPOSITION
Provided is a hair growth-promoting composition comprising: 100 parts by weight of a stem cell culture solution obtained from a culture medium of mesenchymal stem cells which have been subcultured two or more times; 0.001 to 0.1 parts by weight of zinc; 5 to 50 parts by weight of a panthenol based compound; and 0.0001 to 0.1 parts by weight of a water-soluble vitamin, wherein it is sprayed or applied on the scalp to promote hair growth. Said hair growth-promoting composition may have an excellent effect and improve economical efficiency in treating alopecia due to a simple delivery method of the composition.
HAIR GROWTH-PROMOTING COMPOSITION
Provided is a hair growth-promoting composition comprising: 100 parts by weight of a stem cell culture solution obtained from a culture medium of mesenchymal stem cells which have been subcultured two or more times; 0.001 to 0.1 parts by weight of zinc; 5 to 50 parts by weight of a panthenol based compound; and 0.0001 to 0.1 parts by weight of a water-soluble vitamin, wherein it is sprayed or applied on the scalp to promote hair growth. Said hair growth-promoting composition may have an excellent effect and improve economical efficiency in treating alopecia due to a simple delivery method of the composition.
Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing
Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing. Pharmaceutical composition containing antagonists. Methods employing antagonists and agonists for modulation of quorum sensing. Compounds are exemplified by those of formula:
A-[Z].sub.n-L1-[Y].sub.q-W-[V].sub.m-L2-HG,
where A is an acyclic aliphatic group, and HG is an optionally substituted phenyl group. Compounds include those where m and n are both 0, W is —NH—, Y is present and is —CO—CH.sub.2—CO—, and L1 and L2 independently are —[CH.sub.2].sub.p1— and —[CH.sub.2].sub.p2—, where p1 and p2, independently, are 0 or integers ranging from 1-10.